The chronicles of Sensex: The FIIs, The Mutual Funds and The India Inc's growth story. | |||||||||||||||||||||||||||||||||||||||||||||||||||||
|
--
Stay in Touch
ajay@sarthimanagement.com
We have taken due care and caution in compilation of data. Information has been obtained from sources which it considers reliable. However,we does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information.
The chronicles of Sensex: The FIIs, The Mutual Funds and The India Inc's growth story. | |||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Bajaj Electricals Ltd has informed that a meeting of the Board of Directors of the Company will be held on October 26, 2006, inter alia, to consider the following:
1. Declaration of Interim dividend on Unlisted 20,00,000 10% Cumulative Redeemable Non-Participating Preference Shares of Rs 8/- each, on pro-rata bases, for the financial year 2006-07.
2. Exercising of call option for redemption of the said preference shares
-----------------------------------
Coromandel Fertilisers Ltd has informed that a meeting of the Board of Directors of the Company will be held on October 17, 2006, inter alia, to consider the Unaudited financial results for the quarter ended September 30, 2006 and also consider the proposal of merger of M/s. Ficom Organics Ltd (Ficom) and M/s. Rasilah Investments Ltd (a wholly owned subsidiary Company of Ficom) with the Company by way of Scheme of Arrangement.
----------------------------------
Chowgule Steamships Ltd has informed that the Board of Directors of the Company at its meeting held on October 16, 2006, has decided to buy out the entire share capital of Lavgan Dockyard Pvt Ltd (LDPL), an existing Company and thereby making it a 100% subsidiary of the Company.
It is proposed to capitalise the Company by way of further investments towards equity capital for the implementation of the Port Project.
The Board has decided to nominate the following as Additional Directors of LDPL.
1. Mr Vijay V Chowgule
2. Mr M P Patwardhan
----------------------------------
Jet Airways India Ltd has announced the following Unaudited results for the quarter ended September 30, 2006:
The Company has posted a net loss of Rs 551.30 million for the quarter ended September 30, 2006 as compared to net profit of Rs 685.90 million for the quarter ended September 30, 2005. Total Income has increased from Rs 13242.40 million for the quarter ended September 30, 2005 to Rs 18212.30 million for the quarter ended September 30, 2006.
------------------------------------
Wanbury Ltd has informed that the members at the Extra Ordinary General Meeting (EGM) of the Company held on October 17, 2006, have approved the following:
1. The Scheme of Merger of the Pharmaceutical Products of India Ltd with the Company.
2. The Board of Directors of the Company has been authorized to issue and allot Equity Shares & Warrants of the Company to the Members of the Pharmaceutical Products of India Ltd (PPIL) and Equity Shares & OFCDs of the Company to the Secured Creditors of the Pharmaceutical Products of India Ltd.
3. The Scheme of Merger of Doctors Organic Chemicals Ltd with the Company.
4. The Board of Directors of the Company has been authorized to issue and allot Equity Shares of the Company to the Members of Doctors Organic Chemicals Ltd.
-------------------------------------
Ceat Ltd has informed that the members at the 47th Annual General Meeting (AGM) of the Company held on September 25, 2006, inter alia, have accorded to the following:
1. Adoption of Balance sheet and Profit & Loss Account for the year ended March 31, 2006, the Reports of the Auditors thereon & the Report of Directors.
2. Re-appointment of Mr H V Goenka as Chairman of the Company.
3. Re-appointment of Mr Haigreve Khaitan, Mr J N Guzder & Mr K R Podar.
4. Appointment of Auditors.
5. Fixing the remuneration of the Managing Director.
--------------------------------------
Batliboi Ltd has informed that the Board of Directors of the Company at its meeting held on October 14, 2006 has considered and approved the proposal to amalgamate Batliboi SPM Pvt Ltd with the Company pursuant to a Scheme of Amalgamation under Section 391-394 of the Companies Act, 1956.
--------------------------------------
Balrampur Chini Mills Ltd has informed that a meeting of the Board of Directors of the Company will be held on November 14, 2006, inter alia, to consider and approve the audited financial results of the Company for the 18 months period ended September 30, 2006 ( i.e. Financial year 2005-06) and recommendation for payment of final dividend, if any, on the equity shares of the Company for the financial year 2005-2006.
--------------------------------------
Ansal Properties & Infrastructure Ltd has informed that the Company has opted to publish Audited Financial Results for the Half Year ended September 30, 2006 of the Financial Year 2006-2007, instead of publishing the Un-audited Results. Accordingly, the Company shall publish the Audited Financial Results for the said half year period within 2 months from the end of the Half Year September 30, 2006 ( i.e. by November 30, 2006).
-------------------------------------
Sinnar Bidi Udyog Ltd has informed that Shri. Hemant Laxman Shingne resigned as a Director of the Company w.e.f. September 02, 2006.
-------------------------------------
Adf Foods Ltd has informed that the Company will be publishing Audited Half-yearly Financial Results for the half year ended September 30, 2006, within 2 months of the close of the said half-year.
Further the Company has informed that, quarterly un-audited financial results of the Company for the 2nd quarter ended September 30, 2006 will not be published.
------------------------------------
KIC Metaliks Ltd has informed that the members at the Annual General Meeting (AGM) of the Company held on September 23, 2006 have approved issue of 380000 Equity Shares of Rs 10/- each at a premium of Rs 45/- and 909000 Warrants of Rs 55/- each convertible into one Equity Shares of Rs 10/- each to R K Kajaria, Karta of R K Kajaria & Sons (HUF) (Promoter) on Preferential Basis.
-----------------------------------
K M Sugar Mills Ltd has informed that the management has decided to publish Audited Annual Accounts for the year ended at September 30, 2006, with in the period of three months from the end of the quarter ( i.e. December 31, 2006).
-----------------------------------
Amar Remedies Ltd has received ISO 9001:2000 Certificate of compliance from International certification Services (Asia) Pvt Ltd on September 30, 2006 for the companys Quality Management System (QMS) for the scope of development, Manufacturing and supply of Toothpastes, toothpowders and pain relieving balms.
----------------------------------
Monnet Ispat Ltd has informed that a meeting of the Board of Directors of the Company will be held on October 30, 2006, inter alia, to consider Unaudited Financial Results for the quarter ended September 30, 2006 and to consider declaration of interim dividend for the financial year 2006-07.
----------------------------------
Godavari Fertilisers & Chemicals Ltd has informed that the Board of Directors of the Company at its meeting held on October 17, 2006 has approved expansion project for setting up a third granulation plant to enhance the production capacity at Kakinada by 4.25 lakh tones per annum, at an approximate cost of Rs 82.50 crore. The Project is expected to go on stream by early 2009.
----------------------------------
Aksh Optifibre Ltd in association with MTNL on October 17, 2006 has announced the launch of Indias first IPTV Service in Delhi.
The Service will offer traditional television broadcast, video and Music on demand and video calling TV facilities.
---------------------------------
Sun TV Ltd has informed that a meeting of the Board of Directors of the Company will be held on October 27, 2006, inter alia, to consider and take on record the Unaudited financial results of the Company for the quarter ended September 30, 2006 (Q2).
---------------------------------
Glenmark Pharmaceuticals Ltd has informed that Merck KGaA and Glenmark Pharmaceuticals S.A (Switzerland), a wholly owned subsidiary of the Company, have entered into an agreement for Glenmark's DPPIV inhibitor GRC 8200, a treatment for type 2 diabetes in Phase II of clinical development. The transaction is expected to close this year upon approval of the exclusive license to GRC 8200 by the US antitrust agencies under the HSR act.
Under the agreement, Merck KGaA will develop, register and commercialize GRC 8200 for markets in North America, Europe and Japan, white Glenmark will retain commercialization rights for India. The partners will share commercialization rights for other markets in the remainder of the world. Merck KGaA will bear the cost of all ongoing studies and will be responsible for planning, managing and sponsoring all development activities in the future.
The value of all payments to Glenmark could total up to EUR 190 million, including a EUR 25 million up-front payment and various milestone payments upon successful development and launch of mono-therapy and combination products based on GRC 8200. Upon commercial launch, Glenmark will supply the active ingredient to Merck and will receive royalties on net sales of the product.
Mercks Glucophage® (metformin) has been on the market for nearly 50 years and still remains the global gold standard for the oral treatment of type 2 diabetes.
-----------------------------------
Polaris Software Lab Ltd has informed that the Shareholders Committee of the Board of Directors of the Company at its meeting held on October 17, 2006, has allotted 66,785 equity shares of Rs 5/- each to its employees / directors under the Associate Stock Option Plan 2000 & 2001 (ASOP).
------------------------------------
Intec Securities Ltd has informed that the Board of Directors of the Company at its meeting held on October 13, 2006 has allotted 25,00,000 Warrants convertible into equity shares on a preferential basis as follows:
Promoter Group:
1. Pantec Consultants Pvt Ltd : 345000 No of Warrants allotted.
2. Pantec Devices Pvt Ltd : 345000 No of Warrants allotted.
Non-Promoter Group:
1. Walias Multimedia Pvt Ltd : 450000 No of Warrants allotted
2. Edini Steels Pvt Ltd : 450000 No of Warrants allotted
3. Landmark Buildmart Pvt Ltd : 450000 No of Warrants allotted
4. Host Builwell Pvt Ltd : 450000 No of Warrants allotted.
-----------------------------------
Financial Technologies India Ltd has informed that a meeting of the Board of Directors of the Company will be held on October 19, 2006 to consider the proposal for raising funds by way of International / Domestic offering of Securities in one or more tranches to fund the expansion / diversification plans of the company.
-----------------------------------
Zee Telefilms Ltd has informed that a meeting of the Board of Directors of the Company will be held on October 26, 2006, inter alia, to consider and approve the un-audited financial results of the Company for the 2nd quarter and half-year ended September 30, 2006 (Q2).
-----------------------------------
Andhra Pradesh Tanneries Ltd has informed that the members at the 32nd Annual General Meeting (AGM) of the Company held on September 29, 2006, inter alia, have accorded to the following:
1. Adoption of the Balance Sheet as at 31 March, 2006 & the Profit& Loss Account for the year ended on that date together with the Auditors and Directors Reports.
2. Re-appointment of Shri Subramaniam Sundaram as Director of the Company.
3. Appointment of J L Bhatt & Co., Chartered Accountants as the auditors of the Company in place of M/s Rowe & Pal, Chartered Accountants.
-----------------------------------
HDFC Bank Ltd has informed that Mr. Bobby Parikh has resigned from the Board of Directors of the Bank with effect from the close of business hours on October 17, 2006.
Further the Bank has informed that, Mr. Gautam Divan & Mr. C M Vasudev have been appointed as Additional Directors of the Bank.
Nectar Lifesciences Ltd-Sustaining Life
BSE 532649; CMP Rs 163
Nectar Lifesciences is one of the leading players in the cephalosporin market, which is a life saving drug and is in high demand. The company has undertaken capacity expansions and is foraying into new product segments to gain a competitive edge and to cater to the regulated markets. The company is moving up the value chain and undertaking backward integration to cover the whole spectrum.
It has been performing well over the last three years growing at a CAGR of 21% in sales and 40% in PAT. Its NPM is high compared to that of Aurodindo Pharma and Orchid Chem which are dominant players in the cephalosporin market both in the domestic and world markets.
Valuations are attractive at 6x FY06 consolidated earnings (8.0x its standalone FY06).
Investment Rationale
Moving up the value chain and forward integration: Nectar Lifesciences has mainly been an API player in non-regulated markets. It is now looking at moving up the value chain. And to forward integrate, it will be shifting to formulations for which it is setting up a plant in Baddi at a capex of Rs.300m, which is expected to be commissioned in the fourth quarter of FY07. The full effect on revenues will be seen in FY08.
Entering the regulated markets: The company is entering the regulated markets of the US and Europe. To cater to the needs of the regulated markets, the company is increasing the existing cephalosporin capacities in Derabassi and adding capacities in Baddi. It has invested Rs.300mn to set up a formulations unit in Baddi for this purpose. The company will also develop third and fourth generation of Cephalosporin for the regulated markets.
Manufactures high-end cephalosporin: The Company has increased its concentration in the high-end cephalosporin segment. It manufactures the entire range of the product through 7 ACA process which makes Nectar the lowest cost supplier of the entire range of cephalosporins in the country.
Company Outlook
To strengthen its position in the fast-growing Cephalosporins market, the company has undertaken the following strategies
Expansion of the installed capacity in oral and sterile cephalosporin segments.
Setting up additional sterile cephalosporin manufacturing unit at Derabassi.
Addressing high-end Cephalosporin market to ensure superior operating margins.
Forward integration and foray into the manufacture of cephalosporin based formulations.
Backward integration into drug intermediates.
The company is present in the low volume high margin anti-infective segment in the domestic market valued at USD 30bn both in terms of revenue and prescription volume. In view of the growing cepahalosporin market and the company's strive to establish itself as a global player, the company is expected to perform well in the coming quarters.
Nectar has witnessed a CAGR of 21% in net sales over the last three years and going forward it is expected to do well supported by its capacity expansions and forward and backward integration.
Financials
Annual: The company had turned out a good performance in FY06 with the net sales registering a 42% growth, the EBIDTA going up by 134% and the net profit increasing by 58%. The EBIDTA margin improved to 25% compared to 15% in FY05.
Quarterly: The standalone net sales have gone up by 50%. The net profit was up 94%.
Valuations
The stock is trading at 6x its FY06 consolidated earnings, 7.0x its standalone FY06 earning. Nectar trades at much lower PE multiples when compared to companies like Aurobindo Pharma and Orchid Chemicals which are dominant players in Cephalosporins not only in the domestic markets but also globally.